Published in Braz J Med Biol Res on February 24, 2015
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol (2016) 0.81
Diabetes consequences in the fetus liver of the non-obese diabetic mice. Nutr Diabetes (2017) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol (2000) 6.29
Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion (2006) 2.68
Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology (2003) 2.38
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med (2011) 2.34
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA (1999) 2.12
Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol (2007) 1.90
Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol (1999) 1.81
Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2007) 1.52
Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology (2003) 1.48
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol (2010) 1.38
Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal (2005) 1.31
Is liver fibrosis reversible? N Engl J Med (2001) 1.26
Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 1.23
Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med (2007) 1.05
Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). Z Gastroenterol (2007) 1.00
Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol (2012) 0.99
Liver mitochondrial dysfunction and oxidative stress in the pathogenesis of experimental nonalcoholic fatty liver disease. Braz J Med Biol Res (2006) 0.99
Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology (1995) 0.99
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci (2012) 0.98
A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol (2008) 0.98
Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Invest (2008) 0.98
Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol (2011) 0.96
Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem (2011) 0.90
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest (2010) 0.88
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine (2012) 0.86
Nonalcoholic fatty liver disease in the Indian subcontinent: a medical consequence of globalization? Indian J Gastroenterol (2002) 0.85
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. Liver Int (2013) 0.84
Hepatotrophic factors reduce hepatic fibrosis in rats. Arq Gastroenterol (2010) 0.79
[Hepatic lesion in experimental acute pancreatitis. Influence of pancreatic enzyme storage reduction]. Rev Hosp Clin Fac Med Sao Paulo (1999) 0.77